Ionis announces NDA for zilganersen accepted by U.S. FDA for Priority Review

Ionis Pharmaceuticals (IONS) announced that the U.S. Food and Drug Administration, FDA, has accepted for Priority Review the New Drug Application, NDA, for zilganersen, an investigational RNA-targeted medicine for Alexander disease, a rare, progressive and often fatal neurological condition. The FDA has set a Prescription Drug User Fee Act, PDUFA, target action date of September 22, 2026.